New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: What are our therapies likely to be by 2010 and beyond?

American Heart Journal

Volumn 154, Issue 5, 2007, Pages 824-829

  Morrow, John P ^a   Cannon, Christopher P ^b   Reiffel, James A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATORVASTATIN; AZD 7009; AZIMILIDE; CONNEXIN 40; DRONEDARONE; ION CHANNEL; ROTIGAPTIDE; RSD 1235; UNCLASSIFIED DRUG; VERNAKALANT;

ACTION POTENTIAL; CARDIOVERSION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE DURATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; GAP JUNCTION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SINUS RHYTHM; SYMPTOM; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG EVALUATION; HEART RATE; HUMANS; SINOATRIAL NODE; TREATMENT OUTCOME;

EID: 35548991523     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.06.041     Document Type: Review

References (36)

1. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 285 (2001) 2370-2375
2. Le Heusey J.Y., Paziaud O., Piot O., et al. Cost of care distribution in atrial fibrillation patients: COCAF study. Am Heart J 147 (2004) 121-126
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
4. Survival With Oral d-Sotalol. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Lancet 348 (1996) 7-12
5. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
6. The Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Investigators. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
7. The SPAF Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84 (1991) 527-539
8. Hohnloser S.H., Kuck K.H., and Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356 (2000) 1789-1794
9. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004) 1509-1513
10. Carlsson L., Chartier D., and Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol 47 (2006) 123-132
11. Goldstein R.N., Khrestian C., Carlsson L., et al. AZD7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 15 (2004) 1444-1450
12. Crijns H.J., Van Gelder I.C., Walfridsson H., et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 3 (2006) 1321-1331
13. Fedida D., Orth P.M., Chen J.Y., et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 16 (2005) 1227-1238
14. Roy D., Rowe B.H., Stiell I.G., et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 44 (2004) 2355-2361
15. Roy D., Pratt C., Wyse D.G., et al. RSD1235 for conversion of atrial fibrillation. The Phase III Atrial Arrhythmia Conversion Trial. Heart Rhythm 2005 26th Annual Scientific Sessions; May 4-7 (2005)
16. Pritchett E.L., Page R.L., Connolly S.J., et al. Antiarrhythmic effects of azimilide in atrial fibrillation. Efficacy and dose-response. J Am Coll Cardiol 36 (2000) 794-802
17. Pritchett E.L., Kowey P., Connolly S., et al. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J 151 (2006) 1043-1049
18. Kerr C.R., Connolly S.J., Kowey P., et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol 98 (2006) 215-218
19. Gautier P., Guillemare E., Marion A., et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Pharmacol 41 (2003) 191-202
20. Lalevee N., Nargeot J., Barrere-Lemaire S., et al. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol 14 (2003) 885-890
21. Sun W., Sarma J.S., and Singh B.N. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 39 (2002) 677-684
22. Touboul P., Brugada J., Capucci A., et al. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 24 (2003) 1481-1487
23. Singh BN, Hohnloser SH. Dronedarone is safe and effective in maintaining sinus rhythm in atrial fibrillation in patients with pre-specified risk factors. Oral presentation AHA '05 "Pharmacologic Treatment of Arrhythmias" #2366.
24. Davy J.M. Dronedarone demonstrates additional rate control on top of standard pharmacotherapies in the treatment of atrial fibrillation. AHA (2005) [#2737]
25. Sablayrolles S., and Le Grand B. Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent. Curr Opin Invest Drugs 7 (2006) 842-849
26. Dale K.M., and White C.M. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother 41 (2007) 599-605
27. Lee K.W., Everett IV T.H., Rahmutula D., et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114 (2006) 1703-1712
28. Anand K., Mooss A.N., Hee T.T., et al. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 152 (2006) 217-222
29. Gollob M.H., Jones D.L., Krahn A.D., et al. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 354 (2006) 2677-2688
30. Guerra J.M., Everett IV T.H., Lee K.W., et al. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 114 (2006) 110-118
31. Shiroshita-Takeshita A., Sakabe M., Haugan K., et al. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 115 (2007) 310-318
32. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006) 1455-1461
33. Mozaffarian D., Psaty B.M., Rimm E.B., et al. Fish intake and risk of incident atrial fibrillation. Circulation 110 (2004) 368-373
34. Brouwer I.A., Heeringa J., Geleijnse J.M., et al. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am Heart J 151 (2006) 857-862
35. Calo L., Bianconi L., Colivicchi F., et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 45 (2005) 1723-1728
36. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 114 (2006) e257-e354